Programs
Four programs, one data layer underneath
The reader is what exists today and what a clinic can use now. The assays are what the company is for. Both feed the same record, which is what makes the last one possible.
The reader and the record
Software that reads the lateral-flow tests clinics already run — bands or spots, whatever the cassette — and keeps what it read.
This is the part of the company that exists today. It reads assays LateraDX does not manufacture, which is a deliberate choice: it means the software can be useful in a clinic now rather than after an assay program completes.
What it adds first is not a better answer but a durable one. A technician reads a faint line, calls it, and writes a word in the chart; no image is kept and nothing can be reviewed later. Every read here keeps its photograph and its measurement alongside the clinician's conclusion.
Tick-borne and infectious disease
Vector-borne disease is expanding, guidelines call for annual screening, and the panel a clinic can run is fixed by whatever cartridge it bought.
Canine tick-borne screening is among the highest-volume point-of-care testing in veterinary medicine, which makes it both the best proving ground for the reader and a real clinical target in its own right.
Multiplex design lets a panel grow without redesigning the platform, which matters most for the pathogens that are spreading into regions where nobody is currently testing for them.
Targets
- Anaplasma
- Borrelia
- Ehrlichia
- Dirofilaria (heartworm)
- Leptospira
- Leishmania
- Feline retroviruses (FeLV/FIV)
- Bovine respiratory syncytial virus
In development. Nothing on this list is a cleared or approved test.
Oncology and liquid biopsy
Rapid, blood-based tests for cancers that are currently found late, expensively, or both.
Cancer diagnosis in dogs runs through imaging, biopsy and referral — slow, costly, and often reached only once the animal is symptomatic. Circulating protein biomarkers offer a different route: a panel read from blood, at the first visit.
The biological targets came out of peer-reviewed research at The Ohio State University. What remains is engineering rather than discovery — conjugation, strip optimization, multiplexing and validation — which is the work a company is better placed to do than a lab.
Multiplexing is what the approach depends on: single markers are rarely specific enough on their own, and it takes a panel read together to say which cancer, and how advanced.
Targets
- Canine urothelial carcinoma (bladder cancer)
- Canine osteosarcoma
- Pan-cancer marker panel
In development. Nothing on this list is a cleared or approved test.
The data layer
Every reading carries a place and a time. Enough of them and you can see where a disease is moving, not only that the dog in front of you has it.
Rapid tests are run constantly and captured almost nowhere. A result read by eye and written as a word in a chart leaves nothing that can be counted.
Captured instead, with signalment and geography attached, the same tests support questions no single clinic can answer: where a pathogen is emerging, which breeds and ages carry the risk, and how prevalence tracks climate, season and vector activity.
The constraint is density. Aggregated results describe who happened to be testing until coverage is high enough to separate a real rise from a change in who is using the app, so the platform models coverage explicitly and reports which of the two it is looking at.